Bailey v. Janssen Pharmaceutica, Inc.

536 F.3d 1202, 288 F. App'x 597, 2008 U.S. App. LEXIS 16042, 2008 WL 2894742
CourtCourt of Appeals for the Eleventh Circuit
DecidedJuly 29, 2008
Docket07-12258
StatusUnpublished
Cited by45 cases

This text of 536 F.3d 1202 (Bailey v. Janssen Pharmaceutica, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bailey v. Janssen Pharmaceutica, Inc., 536 F.3d 1202, 288 F. App'x 597, 2008 U.S. App. LEXIS 16042, 2008 WL 2894742 (11th Cir. 2008).

Opinion

PER CURIAM:

This opinion is provided as an appendix to our simultaneously issued published opinion in the above-styled case. Finding the district court erred in part in granting appellee’s motion to dismiss, we reverse in part and affirm in part the dismissal of appellant’s First Amended Complaint.

I. BACKGROUND

The decedent, Chad Edgar Beal (“Beal”), died on March 5, 2004, after having received a lethal dose of a pain narcotic, fentanyl, via a transdermal skin patch prescribed to him by his doctor. The prescription patch, Duragesic, was manufactured by defendant Alza Corporation (“Alza”) and distributed by defendant Janssen Pharmaceutiea, Inc. (“Janssen”), both of which are subsidiaries of the holding company, defendant Johnson & Johnson, Inc. (“Johnson & Johnson”). The patch was sold to Beal at a South Florida store of defendant Walgreen Company (“Walgreen”).

Beal undeiwent spinal surgery two days before his death and was prescribed the Duragesic patch by his doctor to help him manage his post-surgical pain. The patch is designed to release a controlled dose of fentanyl, a powerful opiate, to its wearer over a seventy-two-hour period. Despite the box’s warning that the Duragesic patch was “not for acute or postoperative use,” Beal’s doctor prescribed him the medication. 1 Appellant alleges that the patch *600 malfunctioned and delivered to Beal the entire dose of fentanyl at one time, as opposed to slowly over the seventy-two-hour period. Appellant originally brought this action in state court on behalf of Beal, seeking relief under various tort and contract theories for Beal’s wrongful death.

At the time the district court ruled on appellant’s motion to remand, which is the subject of our published opinion, the court also dismissed appellant’s original (state court) complaint on procedural and substantive grounds. This complaint was a typical “shotgun complaint,” and alleged numerous “sub-counts” within each of eight separate counts. For example, Count I of the original complaint, which was, generally, a “strict liability” claim, ' raised sub-claims A through F: strict liability product defect, strict liability failure to warn, breach of warranty of fitness for a particular purpose, breach of warranty of merchantability, fraudulent misrepresentation, and reckless disregard of unreasonable risk of harm. The district court, in dismissing the complaint without prejudice to permit repleader, held: “The Defendants are entitled to a Complaint containing specific allegations of their alleged wrongdoing separated into individual counts.” District Court Order, Docket No. 30, at 5.

The district court, at the time it dismissed appellant’s complaint for repleader, also addressed a number of substantive deficiencies in the complaint. The court noted, chief among the substantive deficiencies, that appellant failed to allege “how, if at all, the patch was defective,” id. at 5, and whether the defect came from the “product’s design or manufacturing process” — or, in other words, whether any purported defect occurred on the assembly line or in the design process. Id. at 6. Further, the original complaint, the district court held, failed to adequately plead strict liability for failure to warn because it did not make a factual allegation that “the warnings were inadequate in light of the generally recognized and prevailing scientific and medical knowledge at the time of manufacture.” Id. at 7. Nor did the complaint allege facts that might establish that the warnings to Beal’s prescribing physician had been inadequate. 2 Appellant’s claims for breach of implied warranties failed for lack of privity between the consumer and all Defendants other than Walgreen, the retailer who sold the product to Beal. The claim for breach of implied warranty of merchantability against Walgreen nevertheless failed because the complaint contained “no allegations that the patch failed during its use in its reasonable and usual manner,” nor did the complaint allege that the product was unmerchanta-ble at the time of sale. Id. at 11.

Following the court’s order dismissing appellant’s original complaint without prejudice, appellant filed an improved and shorter First Amended Complaint, which attempted to overcome the procedural and substantive difficulties highlighted by the district court in its November order. Although the First Amended Complaint did not expressly commingle the claims in the same manner as the original complaint (i.e., not as express sub-claims), the district court still found the First Amended Complaint infirm for procedural and substantive errors not remedied following the earlier dismissal. Among the procedural errors, the court found the allegations “wholly conclusory.” District Court Order, Docket No. 42, at 4. As a result of a typographical error, the first sentence of *601 each count in the First Amended Complaint read: “Plaintiff adopts and realleges the foregoing paragraphs of this complaint as if fully set forth herein.” 3 First Amended Complaint, Docket No. 31, at 13, 18, 20, 22, 23-24, 25, 27, 28 (emphasis added). In effect, then, each subsequent count incorporated into it the prior counts, as well as the preceding factual allegations. Putting aside this typographical error, however, the district court also determined that the complaint commingled claims, albeit in less obvious ways than creating strict subdivisions within a single count. For example, according to the district court, Count I, which is the “strict liability” count, purportedly raised at least five causes of action against all defendants: (1) design defect, (2) manufacturing defect, (3) failure to warn, (4) alter ego/piercing the corporate veil, and (5) conspiracy. Similarly, Count II, for negligence, purportedly raised several individual causes of action under the rubric of “negligence” against all defendants: (1) negligence, (2) design defect, (3) manufacturing defect, (4) failure to warn, (5) alter ego/piercing the corporate veil, and (6) conspiracy. The district court held that because appellant failed to adhere to its earlier instruction that each defendant was “entitled to a Complaint containing specific allegations of their alleged wrongdoing separated into individual counts,” at least in so far as the complaint did not break down claims by defendant into separate counts, that the First Amended Complaint should be dismissed with prejudice.

The district court also, again, found the First Amended Complaint substantively infirm, and ordered its dismissal with prejudice under Fed.R.Civ.P. 12(b)(6). The district court believed that the First Amended Complaint failed to remedy the deficiencies the court had brought to appellant’s attention.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
536 F.3d 1202, 288 F. App'x 597, 2008 U.S. App. LEXIS 16042, 2008 WL 2894742, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bailey-v-janssen-pharmaceutica-inc-ca11-2008.